Ignite Creation Date:
2025-12-24 @ 10:16 PM
Ignite Modification Date:
2025-12-31 @ 11:24 PM
Study NCT ID:
NCT07065435
Status:
RECRUITING
Last Update Posted:
2025-07-15
First Post:
2025-07-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-01
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-01-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-07-02
First Submit QC Date:
None
Study First Post Date:
2025-07-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-13
Last Update Post Date:
2025-07-15
Last Update Post Date Type:
ACTUAL